News
Mr. Weinand is currently a member of the Board of Coya Therapeutics and Replimune, Chairman of the Board of Confo Therapeutics, and Executive Chairman of the Board of Mnemo Therapeutics.
US-based Dieter Weinand is the former CEO of Bayer Pharma with more than 25 years of experience as a senior business leader in the pharmaceutical industryThe appointment comes as AstriVax ...
Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, giving the drugmaker access to an experimental non-opioid pain medicine.
In 2023, Lilly signed a deal with Confo Therapeutics to license its experimental non-opioid drug for neuropathic pain, a condition caused by damage to the nerves outside the brain and spinal cord.
Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), today announced a publication in Nature Communications demonstrating the world’s ...
GHENT, Belgium, October 01, 2024--Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), today announced a publication in Nature ...
Confo Therapeutics, a Belgian firm developing small molecules and antibodies that target G protein–coupled receptors, aims to start testing its drug candidates in humans with the help of $65 ...
Cardiometabolic disease —Confo Therapeutics, a developer of small molecules and antibodies that target G protein-coupled receptors, closed €60 million in financing.
GHENT, Belgium, July 26, 2024--Confo Therapeutics, a clinical-stage company and leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced the closing of a ...
Profile The positions in the table below reflect the Confo Therapeutics's position overall, domestically, within their sector, and in various subject areas based on their Share. Each position ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results